IPM Take
MRD testing is approaching a turning point. Predicting recurrence is important, but the harder question is what clinicians should do with that information. ASCO 2026 data around serial ctDNA and Treatment on MRD suggest the field is moving toward action: escalate, continue, stop or monitor based on molecular dynamics. That is promising, but routine access still needs stronger evidence, guidance and reimbursement.
Executive Summary
Natera announced 35 ASCO 2026 oncology studies, including three oral presentations, focused on molecular residual disease testing and other innovations. The programme highlighted the Treatment on MRD approach, serial testing in colorectal cancer, pan-cancer MRD evidence across 18 published studies, more than 3,000 patients and 15 tumour types, and a new digital Annotation platform integrating clinical, treatment and genomic data with Signatera results.
Why it matters
- Clinicians: Need evidence-based rules for acting on MRD positivity, clearance or molecular progression.
- Payers / HTA bodies: Must distinguish prognostic information from clinically actionable testing.
- Patients / advocates: Earlier recurrence detection should lead to better decisions, not only earlier fear.
A positive ctDNA result can be powerful. It can also be frightening. The difference depends on whether the health system knows what to do next.
That is the central access issue for MRD testing. It is not enough to detect molecular recurrence earlier than imaging. Clinicians need to know whether the result should trigger chemotherapy, treatment extension, trial referral, intensified surveillance or reassurance. Without action rules, a technically advanced test can still leave patients in uncertainty.
The ASCO 2026 MRD package shows the field moving from prognosis toward intervention. Serial testing, molecular clearance, molecular progression and pan-cancer recurrence risk are becoming part of the language of treatment planning. Digital tools may also help place ctDNA results inside the wider patient story rather than as isolated lab values.
For IPM, the message is clear: MRD testing is one of the most important precision oncology access questions now. The test is becoming ready faster than many pathways are.
